TENOR CAPITAL MANAGEMENT Co. L.P. purchased a new stake in Biotech Acquisition (NASDAQ:BIOT) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 280,581 shares of the company’s stock, valued at approximately $2,727,000. TENOR CAPITAL MANAGEMENT Co. L.P. owned approximately 0.98% of Biotech Acquisition at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Karpus Management Inc. bought a new stake in shares of Biotech Acquisition in the first quarter valued at about $243,000. Berkley W R Corp bought a new stake in shares of Biotech Acquisition in the first quarter valued at about $477,000. Goldman Sachs Group Inc. bought a new stake in Biotech Acquisition during the first quarter worth about $584,000. Basso Capital Management L.P. bought a new stake in Biotech Acquisition during the first quarter worth about $747,000. Finally, Alyeska Investment Group L.P. bought a new stake in Biotech Acquisition during the first quarter worth about $875,000. Institutional investors own 22.98% of the company’s stock.
BIOT remained flat at $$9.67 on Thursday. The company had a trading volume of 1,199 shares, compared to its average volume of 35,288. Biotech Acquisition has a fifty-two week low of $9.54 and a fifty-two week high of $9.95. The company has a 50 day moving average price of $9.69.
Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Read More: What is the quiet period?
Want to see what other hedge funds are holding BIOT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biotech Acquisition (NASDAQ:BIOT).
Receive News & Ratings for Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.